Core Viewpoint - The stock of Gilead Sciences-B (01672) rose over 6% following positive data from its oral GLP-1 drug ASC30 for obesity treatment in a Phase IIa study in the U.S. [1] Group 1: Stock Performance - Gilead Sciences-B's stock increased by 6.14%, reaching HKD 13.66, with a trading volume of HKD 35.85 million [1] Group 2: Research and Analyst Insights - Citigroup released a report indicating that the data from the ASC30 study demonstrates its potential as a best-in-class treatment, enhancing confidence in future collaborations [1] - The report maintains a "Buy/High Risk" rating for the stock, with a target price set at HKD 32 [1] Group 3: Company Actions - The company's board believes the current stock price is undervalued and has decided to increase the share buyback fund from a maximum of HKD 300 million to HKD 500 million, based on significant progress in several core pipelines [1]
歌礼制药-B午后拉升逾6% ASC30数据亮眼 公司上调回购资金上限至5亿港元